RCUS Q2 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+440.6% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$76M-804.7% margin

Net Income

-$76M-803.0% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$80M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$899M

Total Liabilities

$294M

Stockholders' Equity

$605M

Cash & Equivalents

$320M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$2M	+440.6%
Gross Profit	$9M	$2M	+440.6%
Operating Income	-$76M	-$45M	-67.8%
Net Income	-$76M	-$45M	-68.5%

Revenue Segments

Gilead Access Rights

$8M82%

Taiho Collaboration Agreement

$2M18%